<DOC>
	<DOCNO>NCT00003972</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know regimen combination chemotherapy effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two regimen combination chemotherapy follow peripheral stem cell transplantation treat patient stage II stage IIIA breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Stage II Stage IIIA Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare early mortality , survival , disease free survival patient node positive stage II IIIA breast cancer treat busulfan , melphalan , thiotepa versus cyclophosphamide , thiotepa , carboplatin follow autologous peripheral blood stem cell transplantation . II . Compare toxicity 2 regimen patient population . OUTLINE : This randomize study . Patients stratify accord stage disease ( stage II v stage IIIA ) , lymph node status ( least 10 positive node vs less 10 positive node ) , hormone receptor status ( estrogen receptor positive progesterone receptor positive v estrogen receptor negative progesterone receptor negative ) . All patient initially receive mobilization chemotherapy cyclophosphamide IV 1-2 hour day 1 paclitaxel IV 4 hour day 2 . Beginning day 4 , patient receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously day final day leukapheresis . When blood count recover , peripheral blood stem cell ( PBSC ) harvest . Patients randomize 1 2 high dose chemotherapy regimens 28-45 day last dose mobilization chemotherapy . Arm I : Patients receive oral busulfan every 6 hour day -8 -6 , melphalan IV 30-60 minute day -5 -4 , thiotepa IV 2 hour day -3 -2 . PBSC reinfused day 0 . Arm II : Patients receive cyclophosphamide , thiotepa , carboplatin continuous IV infusion 24 hour day -7 , -4 . PBSC reinfused day 0 . Beginning 4-6 week last dose chemotherapy , patient arm receive local radiotherapy 5 day week 5 week . Patients also receive oral tamoxifen ( equivalent antiestrogen therapy ) daily 5 year estrogen progesterone receptor positive , postmenopausal , age 50 perimenopausal . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 280 patient ( 140 per treatment arm ) accrue study 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage II breast cancer 1 following : Estrogen receptor negative least 4 positive node OR Estrogen receptor positive least 6 positive node OR Histologically proven stage IIIA breast cancer Must already receive 47 course conventional chemotherapy doxorubicin base regimen ( may include paclitaxel docetaxel ) No great 60 day since induction chemotherapy Prior definitive surgical treatment primary lesion ( modified radical mastectomy breast conserving procedure plus axillary node dissection ) Margins free tumor Hormone receptor status : Estrogen progesterone receptor status know PATIENT CHARACTERISTICS : Age : 18 65 Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 2 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction least 50 % following : Symptoms congestive heart failure Abnormal cardiac exam Prior doxorubicin dose great 400 mg/m2 Pulmonary : No significant pulmonary disease ( DLCO less 60 % predict ) Other : Not pregnant Negative pregnancy test HIV negative No significant active infection No severe disease would severely limit life expectancy No malignancy within past 5 year unless : Chance survival great 5 year 90 % AND Treated surgery ( chemotherapy radiotherapy ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No great 1 prior chemotherapy regimen ( great 7 prior course ) Endocrine therapy : No concurrent tamoxifen Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>